Comment: PD-1 immunotherapy better than chemo alone as first line lung cancer treatment

Dr John Heymach & Prof Richard Schilsky comment on data, during a press conference at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, from a study looking at the use of PD-1 immunotherapy versus chemo alone as first line lung cancer treatment. For more on these results, watch Dr Lopes present the data in the press conference, watch his interview with ecancer and read our news coverage here. https://ecancer.org/video/6912.php https://ecancer.org/news/14118.php Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php

Comment: PD-1 immunotherapy better than chemo alone as first line lung cancer treatment

PD-1 immunotherapy better than chemo alone as first line lung cancer treatment

Pembrolizumab works better than chemotherapy alone as initial treatment for NSCLC

PD-L1 – Immunotherapy: Unleashing the body to fight cancer | Dana-Farber Cancer Institute

Pembrolizumab plus chemo as firstline therapy for NSCLC

First-line treatment decision making for elderly patients with NSCLC

Combination Chemotherapy and Immunotherapy for Patients with High PD-L1 NSCLC - 2022 Program: LCVL

Upfront PD-1 Inhibitor Monotherapy in Advanced NSCLC

Anti–PD-L1 Therapy for Locally Advanced NSCLC

Jack West, MD, on anti-PD-L1/PD-1 therapy in combination with chemotherapy & targeted therapies

GRACEcast - Leading Treatment Options for Patients with Negative Tumor PD-L1 NSCLC with Dr. Stephen

The What, Why, and How of Anti-PD-1/PD-L1 Immunotherapy for Cancer

Challenges associated with biomarker testing for PD-L1 in NSCLC

Jack West, MD, discusses PD-L1/PD-1 therapy in lung cancer treatment algorithms

Debate: Should immunotherapy be used alone? - Yes, immunotherapy could be used alone

Personalizing immunotherapy beyond PDL1 expression

Immunotherapy of Melanoma Targeting PD-1 and Other Inhibitory Receptors

ASCO 2018: Dr. Borghaei Highlights Immunotherapy Findings in Lung Cancer

NEON-1 & NEON-2: ALPN-202 alone or with pembrolizumab in patients with advanced malignancies

Dr. Heymach on Nivolumab for Lung Cancer